Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
Bangkok Post - October 17, 2007
Apiradee Treerutkuarkul
FDA secretary general Siriwat Thiptaradol yesterday said the drug has passed the registration process which took more than three months to complete.
The newly-approved medicine is a generic version of Aluvia, a heat-stable form of second-line Aids drug Kaletra. Both Aluvia and Kaletra are produced by the US-based Abbot Laboratories.
The government in January announced the compulsory licensing policy to bypass patents of the original versions of the second-line Aids drugs.
However, the drugs' patent holder, Abbot Laboratories, opposed the move and offered to cut the price of Kaletra to $1,000 (32,500 baht) per patient per year on a condition that the Public Health Ministry revoke its CL policy.
The ministry rejected the offer, prompting Abbot to freeze registration of Aluvia in Thailand.
GPO board chairman Vichai Chokewiwat said the agency would soon import the first lot of lopinavir/ritonavir from India's generic drug maker Matrix Laboratories.
The amount would be enough for 8,000 HIV-positive people for the next six months.
The price quoted by the Indian drugmaker was at 24,324 baht (US$695) per person per year (2,027 baht per person per month).
Meanwhile, leading cancer drug producers Novartis, Roche Laboratories and Sanofi Aventis will meet the government's price negotiation panel, led by Dr Siriwat, tomorrow to discuss the possibility of a price reduction.
The talks would be the first between the government and the world's leading cancer drug makers after the National Health Security Office last month asked the Public Health Ministry to consider overriding the patents of four cancer drugs - imatinib, letrozole, docetaxel, and erlotinib - as their prices were considered too high.
071017
BP071002
Copyright © 2007 - The Bangkok Post. Reproduction of this article (other than one copy for personal reference) must be cleared through the Bangkok Post.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .